Literature DB >> 18228241

Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms.

Anne-Berit Ekström1, Louise Hakenäs-Plate, Lena Samuelsson, Már Tulinius, Elisabet Wentz.   

Abstract

Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study were to classify a cohort of children with DM1, to describe their neuropsychiatric problems and cognitive level, to estimate the size of the CTG expansion, and to correlate the molecular findings with the neuropsychiatric problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 (CTG repeats > 40) were included in the study. The following instruments were used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental Development Scales, and the Wechsler Scales. Based on age at onset and presenting symptoms, the children were divided into four DM1 groups; severe congenital (n = 19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder was the most common diagnosis present in 35% of the subjects. Eighty-six percent of the individuals with DM1 had mental retardation (MR), most of them moderate or severe MR. ASD was significantly correlated with the DM1 form; the more severe the form of DM1, the higher the frequency of ASD. The frequency of ASD increased with increasing CTG repeat expansions. ASD and/or other neuropsychiatric disorders such as attention deficit hyperactivity disorder, and Tourette's disorder were found in 54% of the total DM1 group. In conclusion, awareness of ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in DM1. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228241     DOI: 10.1002/ajmg.b.30698

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  33 in total

Review 1.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

2.  Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.

Authors:  Nicholas E Johnson; Anne-Berit Ekstrom; Craig Campbell; Man Hung; Heather R Adams; Wei Chen; Elizabeth Luebbe; James Hilbert; Richard T Moxley; Chad R Heatwole
Journal:  Dev Med Child Neurol       Date:  2015-10-28       Impact factor: 5.449

3.  Physical function and mobility in children with congenital myotonic dystrophy.

Authors:  Evan M Pucillo; Deanna L Dibella; Man Hung; Jerry Bounsanga; Becky Crockett; Melissa Dixon; Russell J Butterfield; Craig Campbell; Nicholas E Johnson
Journal:  Muscle Nerve       Date:  2017-02-13       Impact factor: 3.217

4.  Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study.

Authors:  Nicholas E Johnson; Russell Butterfield; Kiera Berggren; Man Hung; Wei Chen; Deanna DiBella; Melissa Dixon; Heather Hayes; Evan Pucillo; Jerry Bounsanga; Chad Heatwole; Craig Campbell
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

5.  Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.

Authors:  Guangbin Xia; Yuanzheng Gao; Shouguang Jin; S H Subramony; Naohiro Terada; Laura P W Ranum; Maurice S Swanson; Tetsuo Ashizawa
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

6.  Orofacial strength, dysarthria, and dysphagia in congenital myotonic dystrophy.

Authors:  Kiera N Berggren; Man Hung; Melissa M Dixon; Jerry Bounsanga; Becky Crockett; Mary D Foye; Yushan Gu; Craig Campbell; Russell J Butterfield; Nicholas E Johnson
Journal:  Muscle Nerve       Date:  2018-09       Impact factor: 3.217

7.  Muscleblind1, but not Dmpk or Six5, contributes to a complex phenotype of muscular and motivational deficits in mouse models of myotonic dystrophy.

Authors:  Anna Matynia; Carina Hoi Ng; Warunee Dansithong; Andy Chiang; Alcino J Silva; Sita Reddy
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

Review 8.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

9.  Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.

Authors:  Guangbin Xia; Katherine E Santostefano; Marianne Goodwin; Jilin Liu; S H Subramony; Maurice S Swanson; Naohiro Terada; Tetsuo Ashizawa
Journal:  Cell Reprogram       Date:  2013-04       Impact factor: 1.987

Review 10.  Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.

Authors:  Genevieve Ho; Michael Cardamone; Michelle Farrar
Journal:  World J Clin Pediatr       Date:  2015-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.